Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2007 2
2008 1
2009 2
2010 3
2012 1
2013 1
2014 5
2015 4
2016 5
2017 4
2018 6
2019 3
2020 7
2021 10
2022 6
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Neuroendocrine neoplasms: Consensus on a patient care pathway.
Hooper J, Jervis N, Morgan L, Beckett V, Hand P, Higgs K, Munir A, Prinn J, Pritchard DM, Sarker D, Srirajaskanthan R, Ellis CB. Hooper J, et al. Among authors: sarker d. J Neuroendocrinol. 2024 Apr;36(4):e13380. doi: 10.1111/jne.13380. Epub 2024 Mar 12. J Neuroendocrinol. 2024. PMID: 38471798 Review.
The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.
Clement DSVM, van Leerdam ME, Tesselaar MET, Cananea E, Martin W, Weickert MO, Sarker D, Ramage JK, Srirajaskanthan R. Clement DSVM, et al. Among authors: sarker d. J Neuroendocrinol. 2024 Apr;36(4):e13376. doi: 10.1111/jne.13376. Epub 2024 Feb 22. J Neuroendocrinol. 2024. PMID: 38389192
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells.
Samain R, Maiques O, Monger J, Lam H, Candido J, George S, Ferrari N, KohIhammer L, Lunetto S, Varela A, Orgaz JL, Vilardell F, Olsina JJ, Matias-Guiu X, Sarker D, Biddle A, Balkwill FR, Eyles J, Wilkinson RW, Kocher HM, Calvo F, Wells CM, Sanz-Moreno V. Samain R, et al. Among authors: sarker d. Sci Adv. 2023 Oct 20;9(42):eadi0244. doi: 10.1126/sciadv.adi0244. Epub 2023 Oct 18. Sci Adv. 2023. PMID: 37851808 Free PMC article.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
McNamara MG, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, Morgan C, Wall LR, Chau I, Reed N, Sarker D, Margetts J, Krell D, Cave J, Sothi S, Anthoney A, Bell C, Patel A, Oughton JB, Cairns DA, Mansoor W, Lamarca A, Hubner RA, Valle JW. McNamara MG, et al. Among authors: sarker d. EClinicalMedicine. 2023 Jun 2;60:102015. doi: 10.1016/j.eclinm.2023.102015. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37287870 Free PMC article.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. Kristeleit R, et al. Among authors: sarker d. Br J Cancer. 2023 Jul;129(1):38-45. doi: 10.1038/s41416-023-02279-x. Epub 2023 Apr 29. Br J Cancer. 2023. PMID: 37120671 Free PMC article. Clinical Trial.
Revitalising cancer trials post-pandemic: time for reform.
Morton C, Sullivan R, Sarker D, Posner J, Spicer J. Morton C, et al. Among authors: sarker d. Br J Cancer. 2023 Apr;128(8):1409-1414. doi: 10.1038/s41416-023-02224-y. Epub 2023 Mar 23. Br J Cancer. 2023. PMID: 36959378 Free PMC article. Review.
Next-generation sequencing and molecular therapy.
Morton C, Sarker D, Ross P. Morton C, et al. Among authors: sarker d. Clin Med (Lond). 2023 Jan;23(1):65-69. doi: 10.7861/clinmed.2022-0514. Clin Med (Lond). 2023. PMID: 36697006 Free PMC article.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter HS, Blagden S, Anthoney A, Klencke BJ, Kowalski MM, Banerji U. Jones R, et al. Among authors: sarker d. Clin Cancer Res. 2023 Jan 17;29(2):331-340. doi: 10.1158/1078-0432.CCR-22-2074. Clin Cancer Res. 2023. PMID: 36378548 Free PMC article. Clinical Trial.
65 results